Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-17T14:55:11.517Z Has data issue: false hasContentIssue false

A controlled trial of cavodil (Pheniprazine) in depression

Published online by Cambridge University Press:  08 February 2018

T. E. Lear
Affiliation:
Department of Psychological Medicine, University College Hospital, London, W.C.1
M. W. Browne
Affiliation:
Netherne Hospital, Coulsdon, Surrey. Formerly in the Department of Psychological Medicine, University College Hospital
J. A. Greeves
Affiliation:
Department of Psychological Medicine, University College Hospital
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

In reviewing controlled trials using mono-amine oxidase inhibitors in the treatment of depression it is soon obvious that workers vary as to whether they consider “depression” as a symptomatic mood change in diverse conditions or as a disease entity. Where the latter occurs, a variety of classifications of depressive illnesses appear, and that most widely used is the broad separation between endogenous and reactive depressions. Other points to note are the authors' definition of improvement, and particularly whether this refers to one aspect of the mental state only and whether the patient left hospital before receiving any treatment other than the drug.

Information

Type
Clinical Trials
Copyright
Copyright © Royal College of Psychiatrists, 1962 
Submit a response

eLetters

No eLetters have been published for this article.